Show simple item record

dc.contributor.authorCheeseman, MD
dc.contributor.authorChessum, NEA
dc.contributor.authorRye, CS
dc.contributor.authorPasqua, AE
dc.contributor.authorTucker, MJ
dc.contributor.authorWilding, B
dc.contributor.authorEvans, LE
dc.contributor.authorLepri, S
dc.contributor.authorRichards, M
dc.contributor.authorSharp, SY
dc.contributor.authorAli, S
dc.contributor.authorRowlands, M
dc.contributor.authorO'Fee, L
dc.contributor.authorMiah, A
dc.contributor.authorHayes, A
dc.contributor.authorHenley, AT
dc.contributor.authorPowers, M
dc.contributor.authorTe Poele, R
dc.contributor.authorDe Billy, E
dc.contributor.authorPellegrino, L
dc.contributor.authorRaynaud, F
dc.contributor.authorBurke, R
dc.contributor.authorvan Montfort, RLM
dc.contributor.authorEccles, SA
dc.contributor.authorWorkman, P
dc.contributor.authorJones, K
dc.date.accessioned2016-12-12T13:29:53Z
dc.date.issued2017-01-12
dc.identifier.citationJournal of medicinal chemistry, 2017, 60 (1), pp. 180 - 201
dc.identifier.issn0022-2623
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/320
dc.identifier.eissn1520-4804
dc.identifier.doi10.1021/acs.jmedchem.6b01055
dc.description.abstractPhenotypic screens, which focus on measuring and quantifying discrete cellular changes rather than affinity for individual recombinant proteins, have recently attracted renewed interest as an efficient strategy for drug discovery. In this article, we describe the discovery of a new chemical probe, bisamide (CCT251236), identified using an unbiased phenotypic screen to detect inhibitors of the HSF1 stress pathway. The chemical probe is orally bioavailable and displays efficacy in a human ovarian carcinoma xenograft model. By developing cell-based SAR and using chemical proteomics, we identified pirin as a high affinity molecular target, which was confirmed by SPR and crystallography.
dc.formatPrint-Electronic
dc.format.extent180 - 201
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAmides
dc.subjectQuinolines
dc.subjectCarrier Proteins
dc.subjectDNA-Binding Proteins
dc.subjectNuclear Proteins
dc.subjectTranscription Factors
dc.subjectLigands
dc.subjectSpectrometry, Mass, Electrospray Ionization
dc.subjectAdministration, Oral
dc.subjectBiological Availability
dc.subjectDrug Discovery
dc.subjectProton Magnetic Resonance Spectroscopy
dc.subjectCarbon-13 Magnetic Resonance Spectroscopy
dc.subjectHeat Shock Transcription Factors
dc.titleDiscovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.
dc.typeJournal Article
dcterms.dateAccepted2016-11-23
rioxxterms.versionofrecord10.1021/acs.jmedchem.6b01055
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of medicinal chemistry
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.publication-statusPublished
pubs.volume60
pubs.embargo.termsNo embargo
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
icr.researchteamMedicinal Chemistry 3
icr.researchteamMedicinal Chemistry 4 (including Analytical Chemistry)
icr.researchteamHit Discovery & Structural Design
dc.contributor.icrauthorCheeseman, Matthew
dc.contributor.icrauthorChessum, Nicola
dc.contributor.icrauthorRichards, Gareth
dc.contributor.icrauthorAli, Salyha
dc.contributor.icrauthorRaynaud, Florence
dc.contributor.icrauthorBurke, Rosemary
dc.contributor.icrauthorVan Montfort, Robert
dc.contributor.icrauthorWorkman, Paul
dc.contributor.icrauthorJones, Keith


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0